- Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation
- The company says Indonesia represents an “exciting market opportunity” as its the largest and most populated country in Southeast Asia, and it’s now in discussions with potential distribution partners
- The VIRALEZE nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets
- Starpharma is also continuing to progress regulatory and commercial activities in multiple other countries
- Shares in Starpharma are up 2.86 per cent, trading at 54 cents at 1:53 pm AEDT
Starpharma (SPL) has registered its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation.
Following the successful registration, the company is in discussions with potential distribution partners in Indonesia.
CEO Jackie Fairley said Indonesia represents an “exciting market opportunity” for the company as the country is the largest and most populous country in Southeast Asia.
“We have seen strong interest in VIRALEZE across Asia, including in Vietnam, and in Hong Kong and Macau where the product recently launched through major pharmacy chains, Mannings and Watsons, as well as selected supermarkets.”
The VIRALEZE nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets.
Starpharma is also continuing to progress regulatory and commercial activities in multiple other countries, including in markets across Southeast Asia.
VIRALEZE is a nasal spray that is intended to physically trap, and block cold and respiratory viruses in the nasal cavity.
Multiple nonclinical studies have shown that VIRALEZE traps and blocks a broad spectrum of respiratory viruses, including human coronaviruses, influenza viruses, rhinoviruses, and respiratory syncytial virus.
Shares in Starpharma were up 2.86 per cent, trading at 54 cents at 1:53 pm AEDT.